Health and Healthcare
Pieris Pharma Soars on AstraZeneca Collaboration
Published:
Last Updated:
Shares of Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) saw perhaps one of the biggest gains on Wednesday after the company announced a critical collaboration with AstraZeneca PLC (NYSE: AZN). Specifically, the two companies are coming together to develop Pieris’ Anticalin platform, including its lead preclinical drug candidate, PRS-060, for the treatment of respiratory diseases.
According to deal, Pieris will receive $57.5 million in upfront and near-term milestone payments. Keep in mind that the company has a total market cap of roughly $151 million. Although, Pieris does have the opportunity to receive up to $2.1 billion in milestone and commercial payments, as well as tiered royalties.
Also under the collaboration, Pieris will be responsible for advancing PRS-060 into Phase 1 clinical trials in 2017. AstraZeneca will fund all clinical development and subsequent commercialization programs, and Pieris has the option of co-development and co-commercialization in the United States from Phase 2a onward.
Additionally, AstraZeneca and Pieris will collaborate to progress four additional novel Anticalins against undisclosed targets for respiratory diseases, with Pieris having the option to co-develop and co-commercialize in the United States two of these programs.
Mene Pangalos, executive vice president, Innovative Medicines and Early Development Biotech Unit and Business Development, commented:
At AstraZeneca, discovering and developing innovative new medicines to treat respiratory diseases is a key strategic priority. Our alliance with Pieris adds an important new modality to our respiratory portfolio and builds on our scientific expertise in inhaled formulation technologies. Pieris shares our passion for ground-breaking science and we look forward to working together to develop new, life-changing treatment options for patients.
Shares of Pieris were trading up nearly 50% at $3.56 on Wednesday, with a consensus analyst price target of $9.00 and a 52-week trading range of $1.30 to $3.90.
AstraZeneca shares were down 0.7% at $30.48. The 52-week range is $25.55 to $35.04, and the consensus price target is $33.87.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
